KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Invested Capital: 2011-2025

Historic Invested Capital for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $1.4 billion.

  • Sarepta Therapeutics' Invested Capital fell 44.62% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 44.62%. This contributed to the annual value of $2.7 billion for FY2024, which is 27.06% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Invested Capital of $1.4 billion as of Q3 2025, which was down 0.09% from $1.4 billion recorded in Q2 2025.
  • Sarepta Therapeutics' Invested Capital's 5-year high stood at $2.7 billion during Q4 2024, with a 5-year trough of $1.0 billion in Q3 2021.
  • Its 3-year average for Invested Capital is $2.0 billion, with a median of $2.0 billion in 2023.
  • Its Invested Capital has fluctuated over the past 5 years, first spiked by 91.12% in 2022, then slumped by 48.07% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Invested Capital stood at $1.5 billion in 2021, then increased by 29.33% to $1.9 billion in 2022, then increased by 8.71% to $2.1 billion in 2023, then increased by 27.06% to $2.7 billion in 2024, then slumped by 44.62% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.1 billion during Q1 2025.